🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the bacteria, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating globally, with estimates suggesting more than 82 million infections per year. Notably increased rates are seen in Africa and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the face of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are deeply concerned about the surge in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, alternatively called a brand name, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists believe that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GSK, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This approval signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on findings detailed in a major medical journal, zoliflodacin eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses an injection and a pill. The research included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have voiced positive views. The availability of a easy-to-administer therapy such as this is seen as a "game-changer" for gonorrhoea control. This is viewed as essential to lessen the impact of the infection for people and to halt the transmission of untreatable gonorrhoea globally.